The European Union’s healthcare regulator the European Medicines Agency (EMA) has decided against a label expansion for GlaxoSmithKline (GSK)’s drug Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) to include asthma.
The EMA also made the same decision for two duplicate GSK products, Elebrato Ellipta and Temybric Ellipta.
Go deeper with GlobalData
Trelegy Ellipta was approved in Europe in November 2017 to relieve symptoms of moderate to severe chronic obstructive pulmonary disease (COPD). GSK was seeking to update the EMA’s marketing authorisation for Trelegy Ellipta, which is a single inhaler triple therapy. GSK’s label expansion called for the drug to be used as a maintenance treatment in adults with asthma who could not control their symptoms with standard-of-care treatment of corticosteroid and long-acting beta-2 agonist (LABA).
GSK’s application was based on the Phase III CAPTAIN study comparing Trelegy Ellipta with only fluticasone furoate and vilanterol in more than 2,000 patients who were able to control their asthma with a LABA and corticosteroid. The primary endpoint of the study was improvement in lung function measured by the change in FEV1 after 24 weeks of treatment.
The EMA decided that improvement in lung function was insufficient to suggest that the COPD drug was suitable for treating asthma. The regulator also noted: “The main study did not clearly show that the medicine was effective at reducing asthma attacks or controlling symptoms.”
The decision comes around six months after the US Food and Drug Administration (FDA) approved the expansion of Trelegy Ellipta’s label to include asthma based on results from the same Phase III CAPTAIN study. In response to the September news, GSK president of R&D and chief scientific officer Dr Hal Barron said: “Millions of asthma patients in the US rely on multiple inhalers to help control their condition and manage their symptoms.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData“Today’s approval is an important advance for these patients as it allows them to benefit from triple therapy by using one inhaler, once-a-day.”
Latest CHMP recommendations
The EMA’s opposing negative decision regarding GSK’s Trelegy Ellipta was made at a recent meeting of the regulator’s Committee for Medicinal Products for Human Use (CHMP).
At the same meeting, the CHMP decided to recommend six new medicines for approval. One example is GSK’s Jemperli (dostarlimab), which received a conditional marketing authorisation in certain types of recurrent or advanced endometrial cancer.
Jemperli is an anti-programmed death-1 monoclonal antibody indicated for endometrial cancer patients whose disease has progressed after platinum-based treatment. GSK is still awaiting FDA approval of Jemperli for this indication.
Another medicine recommended for approval by the CHMP was PTC Therapeutics and Genentech’s Evrysdi (risdiplam) for spinal muscular atrophy patients aged over two months with a clinical diagnosis. Evrysdi is approved in seven countries so far, including the US, Russia, Chile and South Korea.
PTC Therapeutics CEO Stuart Peltz said: “Today’s CHMP opinion marks another important advancement in ensuring Evrysdi is available to SMA patients around the globe.
“Given its proven efficacy and strong safety profile, coupled with the convenience of an at-home administration, we expect Evrysdi to become the treatment of choice for SMA patients and their families.”
The CHMP also recommended label expansions for five medications: Ipsen’s Cabometyx (cabozantinib), GW Pharma’s Epidyolex (cannabidiol oral solution), Bristol Myers Squibb’s Opdivo (nivolumab), Menarini’s antibiotic Quofenix (delafloxacin) and Sanofi’s Sarclisa (isatuximab).
The CHMP also announced it has completed its review of the use of Regeneron and Roche’s monoclonal antibodies REGEN-COV (casirivimab and imdevimab) to treat Covid-19. The committee decided that the antibody combination therapies can be used to treat confirmed patients who do not require supplemental oxygen but are at a high risk of disease progression.
This antibody combination was granted emergency use authorisation by the FDA in November 2020. In the US, REGEN-COV is indicated for adults and over 12s weighing at least 40kg, with confirmed Covid-19 and at high risk of progressing to severe Covid-19 or being hospitalised.
Finally, linked with the CHMP meeting, the EMA has published guidance to manufacturers seeking to modify their Covid-19 vaccines to address emerging Covid-19 variants. The EMA’s guidance paper calls for companies to demonstrate the efficacy of a variant vaccine against the variant strains by providing immunogenicity data. This can be garnered either after primary vaccination with the new, variant vaccine in a Covid-19 naïve unvaccinated population, or after a single dose of the variant vaccine given to individuals who have previously been vaccinated with the company’s original, parent vaccine.
This occurs in the context of the FDA publishing similar guidance for both vaccine and therapeutic manufacturers to combat new Covid-19 variants.
